Latest Pharma Insights
Galleri Panel Aftermath: What Investors And Rivals See Next For MCEDs As FDA Decision Looms
An FDA panel voted in favor of Galleri on safety, effectiveness and benefit-risk, but a split effectiveness vote and advice to avoid “early” framing leave claims, rivals’ strategies and Medicare coverage unsettled, an investor and two rivals told Medtech Insight.
Medtech Insight - October 13, 2026
An FDA panel voted in favor of Galleri on safety, effectiveness and benefit-risk, but a split effectiveness vote and advice to avoid “early” framing leave claims, rivals’ strategies and Medicare coverage unsettled, an investor and two rivals told Medtech Insight.
Medtech Insight - October 13, 2026
Chinese AI-Driven Biotechs Keep Up Fundraising Momentum
LigIT.AI and Nutshell Therapeutics raise new funding for the development of oral cyclic peptides and allosteric drugs, respectively, while multiple other Chinese firms also close new financing rounds.
Scrip - October 13, 2026
LigIT.AI and Nutshell Therapeutics raise new funding for the development of oral cyclic peptides and allosteric drugs, respectively, while multiple other Chinese firms also close new financing rounds.
Scrip - October 13, 2026
DEA Acts On HHS Recommendation To Allow More Room For Risky Derivatives In Kratom Products
DEA changes notice of intent to make 7-OH and MGPI Schedule I controlled substances when either one alone, or combined, exceeds 1mg per gram in solid products or 1mg per milliliter in liquids, or when the ratio of mitragynine to 7-OH, MGPI, or their combined amount is less than 100 to 1.
HBW Insight - October 13, 2026
DEA changes notice of intent to make 7-OH and MGPI Schedule I controlled substances when either one alone, or combined, exceeds 1mg per gram in solid products or 1mg per milliliter in liquids, or when the ratio of mitragynine to 7-OH, MGPI, or their combined amount is less than 100 to 1.
HBW Insight - October 13, 2026
‘Biggest Beauty Blindspot’: Non-Profit Pushes Lip Product Safety Framework
A new nonprofit aims to modernize global safety standards for lip products, citing outdated models and changes in how consumers are utilizing the products.
HBW Insight - October 13, 2026
A new nonprofit aims to modernize global safety standards for lip products, citing outdated models and changes in how consumers are utilizing the products.
HBW Insight - October 13, 2026
Chinese AI-Driven Biotechs Keep Up Fundraising Momentum
LigIT.AI and Nutshell Therapeutics raise new funding for the development of oral cyclic peptides and allosteric drugs, respectively, while multiple other Chinese firms also close new financing rounds.
Scrip - October 13, 2026
LigIT.AI and Nutshell Therapeutics raise new funding for the development of oral cyclic peptides and allosteric drugs, respectively, while multiple other Chinese firms also close new financing rounds.
Scrip - October 13, 2026
Galleri Panel Aftermath: What Investors And Rivals See Next For MCEDs As FDA Decision Looms
An FDA panel voted in favor of Galleri on safety, effectiveness and benefit-risk, but a split effectiveness vote and advice to avoid “early” framing leave claims, rivals’ strategies and Medicare coverage unsettled, an investor and two rivals told Medtech Insight.
Medtech Insight - October 13, 2026
An FDA panel voted in favor of Galleri on safety, effectiveness and benefit-risk, but a split effectiveness vote and advice to avoid “early” framing leave claims, rivals’ strategies and Medicare coverage unsettled, an investor and two rivals told Medtech Insight.
Medtech Insight - October 13, 2026
DEA Acts On HHS Recommendation To Allow More Room For Risky Derivatives In Kratom Products
DEA changes notice of intent to make 7-OH and MGPI Schedule I controlled substances when either one alone, or combined, exceeds 1mg per gram in solid products or 1mg per milliliter in liquids, or when the ratio of mitragynine to 7-OH, MGPI, or their combined amount is less than 100 to 1.
HBW Insight - October 13, 2026
DEA changes notice of intent to make 7-OH and MGPI Schedule I controlled substances when either one alone, or combined, exceeds 1mg per gram in solid products or 1mg per milliliter in liquids, or when the ratio of mitragynine to 7-OH, MGPI, or their combined amount is less than 100 to 1.
HBW Insight - October 13, 2026
‘Biggest Beauty Blindspot’: Non-Profit Pushes Lip Product Safety Framework
A new nonprofit aims to modernize global safety standards for lip products, citing outdated models and changes in how consumers are utilizing the products.
HBW Insight - October 13, 2026
A new nonprofit aims to modernize global safety standards for lip products, citing outdated models and changes in how consumers are utilizing the products.
HBW Insight - October 13, 2026
Outlook Promotes Eylea Executive To Helm Lytenava Launch
Outlook Therapeutics has promoted to the role of chief commercial officer Greg DiPasquale – who has previously been instrumental in brand launches such as Beovu, Eylea, Eylea HD and Triesence – in preparation for its US launch of Lytenava.
Generics Bulletin - October 12, 2026
Outlook Therapeutics has promoted to the role of chief commercial officer Greg DiPasquale – who has previously been instrumental in brand launches such as Beovu, Eylea, Eylea HD and Triesence – in preparation for its US launch of Lytenava.
Generics Bulletin - October 12, 2026
Thyme Therapeutics Announces Plans To Build A Lower-Cost Oncology Biosimilars Model
US-based Thyme Companies has announced the launch of biosimilars venture Thyme Therapeutics to establish a new sustainable approach to the commercialization of oncology products.
Generics Bulletin - October 12, 2026
US-based Thyme Companies has announced the launch of biosimilars venture Thyme Therapeutics to establish a new sustainable approach to the commercialization of oncology products.
Generics Bulletin - October 12, 2026
Execs On The Move: September 2026
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - October 12, 2026
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - October 12, 2026
LSX USA: China Will Dominate Years 4–12 Of Drug Development, Say Investors
Investors described a relay in which the US leads early science, China leads mid-stage development and the US returns for late-stage trials and commercialization, with licensing structure, policy risk and pricing shaping who benefits.
In Vivo - October 12, 2026
Investors described a relay in which the US leads early science, China leads mid-stage development and the US returns for late-stage trials and commercialization, with licensing structure, policy risk and pricing shaping who benefits.
In Vivo - October 12, 2026